NCT05844332Completed
LUTATHERA Injection General Use Result Survey
LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)
Source: ClinicalTrials.gov · Last updated 22 Dec 2025
Brief summary (registry, in English)
This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 347 (actual)
- First submitted
- 25 Apr 2023
- Start date
- 17 Dec 2021
- Primary completion date
- 27 Jun 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT05844332
What you commit to
- Study type: Observational
- Participants enrolled: 347
- From 17 Dec 2021 to the primary completion date, 27 Jun 2024
- 41 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not applicable
Who the study is looking for
- All patients treated with this drug for the following indications during a certain post-marketing period
- Indication: Somatostatin receptor-positive neuroendocrine tumor Patients who started to receive this drug before the contract for this study will also be included in the study population and it will be allowed to register them after the contract so that all patients who receive this drug will be included in this study. Patients treated with this drug for off-label indication will also be included in this study to register all patients received this drug.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (41)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.